Business Context and Reporting Period
Lifecore Biomedical, Inc. (LFCR) filed this Form 8-K on October 30, 2023, to announce a non-reliance on previously issued financial statements. The Audit Committee concluded that consolidated financial statements for fiscal years ended May 29, 2022, and May 30, 2021, as well as various interim periods through February 26, 2023, and the fourth quarter of fiscal 2023, should no longer be relied upon due to identified errors.
Key Financial Metrics
This filing does not provide specific updated revenue, profit, cash flow, or debt figures. Instead, it details the nature of accounting errors requiring restatement:
- Revenue and Cost of Sales: Errors related to principal vs. agent accounting in the Lifecore segment for FY21.
- Inventory: Required write-downs to net realizable value for FY21 and FY22, which will increase costs of sales.
- Interest Expense: Errors in capitalizing interest on assets under construction for FY21 and FY22, which will reduce interest expense and increase property and equipment.
- Retained Earnings: Adjustments to FY21 opening retained earnings for the Lifecore segment and the former Curation Foods segment regarding uncollectible receivables.
Material Changes Versus Prior Period
The filing identifies material weaknesses in internal controls over financial reporting as of May 29, 2022. The primary material change is the determination that prior financial statements contained errors involving capitalized interest calculations, inventory valuation, and adjustments related to previously divested businesses. These errors were previously considered immaterial individually but are now being restated.
Guidance, Outlook, and Risks
Management Commentary: The Company expects the restatement to have no adverse effect on its operations or liquidity. The restated figures will be included in the Annual Report on Form 10-K for the fiscal year ended May 28, 2023.
Risks and Contingencies:
- Investors are advised not to rely on financial information for the "Non-Reliance Periods" until the restatement is filed.
- Forward-looking statements regarding the timing of the amended reports are subject to risks, including the timing of the audit by Ernst & Young LLP and the potential discovery of additional information.
Investor Verification Checklist
- Verify the final restated financial figures once the 2023 Annual Report (Form 10-K) is filed.
- Monitor the timeline for the filing of amended reports, as delays are a noted risk.
- Review the impact of the inventory write-downs and capitalized interest adjustments on historical profitability metrics.
- Confirm the status of the material weaknesses in internal controls and any remediation plans disclosed in future filings.